Delayed or upfront brain radiotherapy in treatment-naïve lung cancer patients with asymptomatic or minimally symptomatic brain metastases and ALK rearrangements (DURABLE). 1 BRAF V600-mutated tumors ...
ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of cutaneous ...
Rocket Pharmaceuticals' shares rallied ahead of the opening bell after the Food and Drug Administration lifted its clinical hold on the biotechnology company's Phase 2 trial of its RP-A501 treatment ...
Demonstrated a favorable safety and tolerability profile for VG-3927 across all cohorts, including elderly participants, with no serious adverse events reported. Achieved robust and dose-dependent ...
Beijing QL Biopharmaceutical has shared phase 2 data on its once-monthly GLP-1 candidate, providing early evidence that the ultra-long-acting prospect can match the efficacy of weekly products from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback